A vasopressin receptor is a cell surface receptor which binds vasopressin.[1][2] The three types of vasopressin receptor are members of the A6 subfamily of G-protein coupled receptors.
[edit] Subtypes
Humans express three subtypes: 1A, 1B and 2[2]
[edit] Function
Although all three of these proteins are G-protein coupled receptors (GPCRs), activation of AVPR1A and AVPR1B stimulate phospholipase C, while activation of AVPR2 stimulates adenylate cyclase.[2] These three receptors for vasopressin have unique tissue distributions. AVPR1A are expressed in vascular smooth muscle cells, hepatocytes, platelets, brain cells, and uterus cells. AVPR1B are expressed in cells of the anterior pituitary and throughout the brain, especially in the pyramidal neurons of the hippocampal CA2 field. AVPR2 are expressed in the kidney tubule, predominantly in the distal convoluted tubule and collecting ducts, in fetal lung tissue and lung cancer, the last two being associated with alternative splicing. AVPR2 is also expressed in the liver where stimulation releases a variety of clotting factors into the bloodstream. In the kidney, AVPR2's primary function is to respond to arginine vasopressin by stimulating mechanisms that concentrate the urine and maintain water homeostasis in the organism. When the function of AVPR2 is lost, the disease Nephrogenic Diabetes Insipidus (NDI) results.[3]
[edit] Role in Disease Treatment
Vasopressin receptor antagonists are drugs that block the action that occurs at the vasopressin receptor to treat diseases. The most common disease these are used to treat is hyponatremia, which causes serious complications for such illnesses as liver cirrhosis and congestive heart failure. Vasopressin receptor antagonists include the new class of "vaptan drugs", including lixivaptan.
[edit] References
- ^ Peter J, Burbach H, Adan RA, Lolait SJ, van Leeuwen FW, Mezey E, Palkovits M, Barberis C (October 1995). "Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family". Cell. Mol. Neurobiol. 15 (5): 573–95. doi:10.1007/BF02071318. PMID 8719042.
- ^ a b c Birnbaumer M (December 2000). "Vasopressin receptors". Trends Endocrinol. Metab. 11 (10): 406–10. doi:10.1016/S1043-2760(00)00304-0. PMID 11091117.
- ^ Spanakis E, Milord E, Gragnoli C (December 2008). "AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance". J. Cell. Physiol. 217 (3): 605–17. doi:10.1002/jcp.21552. PMID 18726898.
[edit] External links
|
|
|
Class A:
Rhodopsin like |
|
|
|
|
|
Metabolites and
signaling molecules
|
|
|
|
Peptide
|
|
|
|
Miscellaneous
|
|
|
|
| Class B: Secretin like |
|
|
Class C: Metabotropic
glutamate / pheromone |
|
|
Class F:
Frizzled / Smoothened |
|
|
B trdu: iter (nrpl/grfl/cytl/horl), csrc (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd; path (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp)
|
|
|
|
|
| G protein-coupled receptor |
|
|
|
|
|
|
|
|
|
Other neuropeptide receptors
|
|
|
|
| Type I cytokine receptor |
|
|
| Enzyme-linked receptor |
|
|
| Other |
|
|
B trdu: iter (nrpl/grfl/cytl/horl), csrc (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd; path (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp)
|
|
|
|
|
| Cholecystokinin |
|
|
| CRH |
|
|
| Galanin |
|
|
| Ghrelin |
|
|
| MCH |
|
|
| Melanocortin |
|
|
| Neuropeptide S |
|
|
| Neuropeptide Y |
|
|
| Neurotensin |
|
|
| Opioid |
|
|
| Orexin |
|
|
| Oxytocin |
|
|
| Tachykinin |
|
|
- Agonists: Substance P
Antagonists: Aprepitant
- Befetupitant
- Casopitant
- CI-1021
- CP-96,345
- CP-99,994
- CP-122,721
- Dapitant
- Ezlopitant
- FK-888
- Fosaprepitant
- GR-203,040
- GW-597,599
- HSP-117
- L-733,060
- L-741,671
- L-743,310
- L-758,298
- Lanepitant
- LY-306,740
- Maropitant
- Netupitant
- NKP-608
- Nolpitantium
- Orvepitant
- RP-67,580
- SDZ NKT 343
- Vestipitant
- Vofopitant
|
|
|
|
|
|
|
|
|
|
|
| Vasopressin |
|
|